Adjuvant Atezolizumab Improves Disease-Free Survival in Resected PD-L1–Positive NSCLC

Despite undergoing complete surgical resection, many patients with stage IB–IIIA non–small-cell lung cancer (NSCLC) suffer recurrent metastatic disease. Adjuvant platinum-based combination chemotherapy, the current standard of care for these patients, results in a modest 4% to 5% overall survival improvement. Recently, adjuvant osimertinib therapy produced significant disease-free survival improvement in patients whose resected lung cancer harbored EGFR mutations.

The phase 3 IMpower010 trial randomized 1005 patients with stage IB–IIIA NSCLC who had undergone complete resection and adjuvant chemotherapy to either adjuvant atezolizumab for one year or best supportive care. Treatment with atezolizumab led to statistically significant improveme…